ArticleInternational journal of women's health2025
Hepatic Angiosarcoma with eosinophilia: A Case Report and Literature Review.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatic angiosarcoma is an extremely rare, uncontrollable tumor with strong invasion, high mortality rate, and extremely poor prognosis. There is first report on hepatic angiosarcoma accompanied by eosinophilia. Case Presentation: A woman with a chief complaint of poor appetite for about 3 months presented to a local hospital with a liver mass. Laboratory examination revealed a significant increase in eosinophils count was 9.58% in the serum. Abdominal MRI revealed multiple focal high-density lesions in the liver and spleen, and cranial MRI revealed multiple high-density shadows in the skull. Laparoscopic biopsy revealed a hepatic angiosarcoma and targeted treatment with Anlotinib was performed. Two months later, the patient died of splenic rupture and bleeding. Conclusion: Hepatic angiosarcoma often has no specific clinical manifestations, and we found that this case can lead to an increase in eosinophils, which is worth the attention of clinical physicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.